Ascendis Pharma A/S (NASDAQ:ASND) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research note issued to investors on Monday morning, The Fly reports. The firm issued an overweight rating on the biotechnology company’s stock.

ASND has been the topic of several other research reports. Wedbush started coverage on Ascendis Pharma A/S in a research note on Friday, June 26th. They issued a buy rating and a $188.00 price objective on the stock. CSFB upped their price objective on Ascendis Pharma A/S from $149.00 to $154.00 and gave the company an outperform rating in a research note on Wednesday, May 20th. Zacks Investment Research downgraded Ascendis Pharma A/S from a hold rating to a sell rating in a research note on Wednesday, September 2nd. BidaskClub upgraded Ascendis Pharma A/S from a sell rating to a hold rating in a research note on Wednesday, September 9th. Finally, Morgan Stanley increased their target price on Ascendis Pharma A/S from $177.00 to $179.00 and gave the stock an overweight rating in a research report on Monday, August 31st. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $168.67.

Shares of NASDAQ ASND opened at $145.03 on Monday. Ascendis Pharma A/S has a twelve month low of $90.06 and a twelve month high of $158.93. The stock’s 50 day moving average price is $142.39 and its 200-day moving average price is $135.67. The company has a market capitalization of $7.66 billion, a PE ratio of -23.78 and a beta of 0.87. The company has a quick ratio of 9.04, a current ratio of 9.04 and a debt-to-equity ratio of 0.06.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Thursday, August 27th. The biotechnology company reported ($1.97) EPS for the quarter, missing the consensus estimate of ($1.66) by ($0.31). Ascendis Pharma A/S had a negative net margin of 3,130.03% and a negative return on equity of 45.97%. The firm had revenue of $1.58 million during the quarter, compared to analysts’ expectations of $2.47 million. As a group, research analysts expect that Ascendis Pharma A/S will post -7.26 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. increased its holdings in shares of Ascendis Pharma A/S by 17.4% in the first quarter. RA Capital Management L.P. now owns 4,914,955 shares of the biotechnology company’s stock worth $553,473,000 after purchasing an additional 729,613 shares during the period. FMR LLC increased its stake in Ascendis Pharma A/S by 0.5% in the second quarter. FMR LLC now owns 4,798,583 shares of the biotechnology company’s stock valued at $709,710,000 after acquiring an additional 24,620 shares during the last quarter. Vivo Capital LLC bought a new position in Ascendis Pharma A/S in the first quarter valued at $225,574,000. Janus Henderson Group PLC increased its stake in Ascendis Pharma A/S by 49.0% in the first quarter. Janus Henderson Group PLC now owns 1,867,190 shares of the biotechnology company’s stock valued at $210,264,000 after acquiring an additional 614,186 shares during the last quarter. Finally, Spyglass Capital Management LLC increased its stake in Ascendis Pharma A/S by 40.0% in the first quarter. Spyglass Capital Management LLC now owns 351,388 shares of the biotechnology company’s stock valued at $39,570,000 after acquiring an additional 100,416 shares during the last quarter. 91.39% of the stock is currently owned by hedge funds and other institutional investors.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

See Also: Can systematic risk be avoided?

The Fly

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.